Non-tuberculous mycobacteria, often abbreviated NTM, are environmental organisms that increasingly cause chronic and debilitating lung disease worldwide. Among them, Mycobacterium abscessus stands out as particularly menacing. It is naturally resistant to many standard antibiotics, it can form ropelike cords that shield it from engulfment by immune cells, and it thrives in patients with pre-existing lung damage such as bronchiectasis, cystic fibrosis, or pulmonary fibrosis. Treatment regimens typically stretch for many months, involve multiple toxic drugs, and frequently fail to eradicate the infection. Against this grim clinical backdrop, the question of how the immune system naturally fights M. abscessus has remained surprisingly underexplored, particularly with respect to γδ T cells, an unconventional lymphocyte population whose role in NTM infection had never been systematically characterized.

γδ T cells differ from the conventional αβ T cells that dominate textbook immunology. Rather than recognizing peptide fragments presented by major histocompatibility molecules, they respond rapidly to a wide range of stress signals and microbial products, earning them a reputation as a bridge between innate and adaptive immunity. A major subset of these cells produces interleukin-17A, a powerful inflammatory cytokine best known for recruiting neutrophils and shaping defenses at body surfaces. To determine whether these cells matter in M. abscessus infection, the researchers built a mouse model of pulmonary infection and mapped the immune landscape of lung tissue over the early days of disease using single-cell RNA sequencing, a technique that captures the gene expression profile of thousands of individual cells simultaneously.

The single-cell atlas revealed a striking pattern. As infection took hold, γδ T cells accumulated in the lung and expanded a population that expressed high levels of IL-17A. When the team removed γδ T cells entirely, using mice genetically engineered to lack them, the consequences were dramatic: bacteria persisted at far higher levels in the lungs and spleens, and lung inflammation worsened. Conversely, when γδ T cells were depleted in animals that had already cleared a first infection and were then re-challenged, the protective advantage of prior exposure evaporated. These experiments established γδ T cells as indispensable players in the early defense against M. abscessus, a finding that had not been demonstrated before for any non-tuberculous mycobacterial pathogen.

Delving deeper, the investigators identified IL-17A itself as the linchpin of this protective response. Mice unable to produce IL-17A lost much of their capacity to control the infection, and importantly, the defect traced back to the γδ T cells themselves. Without IL-17A signaling, the cells became less adept at recognizing the bacterium and lost much of their cytotoxic firepower. In an elegant series of transfer experiments, IL-17A-deficient γδ T cells failed to protect infected animals, whereas their normal counterparts succeeded. This revealed something unusual: IL-17A was not merely acting as a broadcast signal to other immune players but was required within the γδ T cells themselves, a cell-intrinsic requirement that underscores how tightly the cytokine and its producer are wired together during this infection.

The mechanism by which these cells actually kill the bacterium proved to be equally instructive. M. abscessus is an extracellular pathogen during key phases of infection, residing outside host cells in the airways and tissue spaces. The researchers found that IL-17A-positive γδ T cells eliminated extracellular bacteria through a granzyme B-dependent cytotoxic pathway. Granzyme B is a serine protease classically associated with the destruction of virus-infected or malignant cells, delivered through pore-forming perforin or other release mechanisms. Its deployment against free-living bacteria adds a new dimension to the antimicrobial portfolio of γδ T cells and explains how a lymphocyte population usually discussed in the context of autoimmunity and inflammation can act as a direct bactericidal weapon.

How, then, does the immune system know to mobilize these cells in the first place? The answer lies in a cascade that begins with Toll-like receptor 2, a pattern-recognition receptor on macrophages that detects components of the bacterial cell wall. When M. abscessus engaged TLR2 on lung macrophages, the macrophages responded by secreting two cytokines, interleukin-1β and interleukin-23. This cytokine pair is a well-known stimulus for IL-17 production in T cells, and in this context it drove both the expansion and the activation of the IL-17A-positive γδ T cell population. Blocking either IL-1β or IL-23 in infected mice diminished the γδ T cell response and impaired bacterial control, mapping out a complete signaling axis that runs from bacterial recognition through macrophage activation to lymphocyte mobilization and, ultimately, bacterial killing.

Perhaps the most clinically resonant aspect of the study concerns patients whose immunity depends on interferon-gamma, the canonical cytokine for defense against mycobacteria. A subset of individuals, particularly in Southeast Asia, develops autoantibodies that neutralize their own interferon-gamma, leaving them exquisitely vulnerable to disseminated NTM infections. Using single-cell RNA sequencing of peripheral blood cells from NTM patients, the researchers found evidence that anti-interferon-gamma autoantibodies compromise γδ T cell function in humans, mirroring what they observed in mice lacking the interferon-gamma receptor. Crucially, in mice engineered without functional interferon-gamma signaling, IL-17A-positive γδ T cells still conferred protection, and the same held true in a model combining M. abscessus infection with bleomycin-induced pulmonary fibrosis. In other words, this arm of immunity operates independently of the interferon-gamma axis and remains effective even in scarred, damaged lungs.

The implications for therapy are considerable. Current treatment of NTM disease relies almost entirely on antibiotics that the pathogen is adept at resisting, and there are no licensed immunotherapies that bolster host defenses. If the pathways defined in this study can be harnessed in patients, whether by stimulating IL-1β and IL-23 signaling, expanding protective γδ T cell populations, or delivering IL-17A-driven cytotoxic activity directly, clinicians could gain a means of strengthening the lung’s own antimicrobial machinery. Such approaches would be especially valuable for the growing population of patients with anti-interferon-gamma autoantibodies or structural lung disease, for whom conventional regimens offer diminishing returns. The researchers caution that translating mouse findings to the clinic will require careful work, particularly because IL-17A is also implicated in inflammatory conditions such as psoriasis and could carry safety risks if induced systemically. Nevertheless, the identification of a concrete, mechanistically defined cell type that can clear M. abscessus marks a genuine advance. It transforms γδ T cells from immunological bystanders into a promising therapeutic target, and it reframes the fight against antibiotic-resistant mycobacteria as a battle that the immune system, with the right encouragement, may be able to win on its own terms.

Subject of Research: The role of IL-17A-producing γδ T cells in controlling pulmonary Mycobacterium abscessus infection in mice.

Article Title: IL-17A-producing γδ T cells control pulmonary Mycobacterium abscessus infection in mice

Article References: Hu, X., Lin, S., Meng, W., Liu, H., Qin, Z., Wu, Z., Wan, Y., Ma, S., Yang, X., Yin, Z., Chu, Y., Zhang, W., Shao, L., & Lin, Y. (2026). IL-17A-producing γδ T cells control pulmonary Mycobacterium abscessus infection in mice. Nature Microbiology. https://doi.org/10.1038/s41564-026-02466-5

Image Credits: AI Generated

DOI: 10.1038/s41564-026-02466-5

Keywords: Mycobacterium abscessus, non-tuberculous mycobacteria, γδ T cells, IL-17A, interferon-gamma, granzyme B, TLR2, IL-1β, IL-23, pulmonary infection, immunology, antibiotic resistance

Researchers employed cutting-edge whole-genome sequencing to explore the relationship between bacterial genetic variation and antimicrobial tolerance. By analyzing an extensive dataset of 1.3 million M. abscessus unitigs, which are sequence fragments capturing diverse genomic variations, the team mapped these to phenotypic profiles of drug resistance and tolerance. Using linear mixed models, which account for complex genetic relationships and environmental factors, they could carefully dissect the fraction of phenotypic variance attributable to genetic variance—a measure known as heritability.

The most striking revelation from their analysis was the high heritability of tolerance phenotypes across various antibiotics. Contrary to prior assumptions of tolerance being primarily a plastic, non-genetic feature, the data indicate that for many drugs, genetic determinants account for between 32% and an astonishing 97% of the variability in tolerance levels between isolates. This far exceeds the minimal 1.1% heritability expected by chance, underscoring the heritable and strain-specific nature of drug killing phenotypes.

The team further contrasted heritability estimates between drug resistance, measured as minimum inhibitory concentrations (MICs), and tolerance, assessed via the area under the killing curve (AUC), highlighting that while resistance to some antibiotics such as macrolides was strongly genetically determined, others like imipenem and cefoxitin showed low heritability. This likely reflects the interplay of drug chemical properties and biological variability affecting phenotypic measurements, providing critical insights into heterogeneity in resistance and tolerance mechanisms.

Beyond quantifying heritability, the researchers integrated these data with detailed phylogenetic analyses of over 350 M. abscessus isolates. This evolutionary perspective enabled them to characterize how tolerance traits have emerged and been conserved across bacterial lineages. Strikingly, both convergent evolution and clade-specific inheritance patterns were evident. For example, distinct high- or low-tolerance phenotypes have evolved independently multiple times—a phenomenon known as homoplasy—while other traits are inherited within closely related clades.

One particularly noteworthy finding was the identification of a low tigecycline tolerance clade nested within the dominant circulating clone of M. abscessus massiliense. This clade also harbors high-level mutational resistance to aminoglycosides and macrolides and is associated with increased virulence, highlighting a paradox where high genetic drug resistance coincides with vulnerabilities in drug tolerance. The low tolerance to tigecycline within this clade could represent an exploitable therapeutic weakness, offering new avenues to improve treatment outcomes for infections notoriously difficult to manage.

The implications of this study extend far beyond mere academic interest. Understanding that tolerance, like resistance, has a strong genetic basis challenges established dogma and opens new research pathways. Therapeutic strategies could be refined considering not only resistance profiles but also tolerance genotypes, enabling more precise combination therapies that prevent both survival and proliferation of pathogenic strains.

Equally remarkable is the study’s demonstration that large-scale phenotypic screens coupled with whole genome sequencing and sophisticated statistical modeling provide a powerful lens to map the complex genotype-phenotype landscape in microorganisms. This approach serves as a blueprint for dissecting genetic contributions to other complex traits in diverse infectious agents, potentially revolutionizing antimicrobial stewardship and drug development.

Moreover, the heterogeneity observed in both resistance and tolerance suggests that treatment failures and relapses in mycobacterial infections may stem as much from genetically encoded tolerance as from resistance mutations. Clinical microbiology diagnostics may need to incorporate tolerance assessments, enhancing predictive precision for therapeutic success and reducing the mounting burden of chronic infections.

This research also spotlights the nuanced relationships between genetic variation, bacterial physiology, and antimicrobial lethality, emphasizing that phenotypic assays alone cannot capture the full biology of tolerance. Comprehensively integrating high-resolution genotype data enables identification of subtle genetic variants controlling tolerance across populations, which could be missed by conventional methods.

By mapping killing phenotypes onto the bacterial phylogeny, the study reveals how evolutionary pressures shape drug response strategies in bacterial populations. These dynamics of clonal inheritance and repeated emergence of similar traits underscore evolutionary constraints and plasticity in antimicrobial survival mechanisms, encouraging deeper evolutionary-informed drug design.

Ultimately, this work represents a paradigm shift with wide-reaching consequences for clinicians, microbiologists, and pharmacologists. The discovery that drug tolerance is not simply a transient phenotypic state but is robustly genetically encoded gives actionable insight into combatting mycobacterial infections with higher lethality rates and poorer clinical outcomes. A refined understanding of the genetic landscape controlling tolerance holds promise for enhanced diagnostics, targeted therapeutics, and improved patient prognoses worldwide.

As multidrug-resistant infections continue to jeopardize global health, deciphering the genetic architecture of tolerance in pathogens like M. abscessus emerges as an urgent priority. This seminal study lays vital groundwork for future investigations and therapeutic innovations that can transform our ability to outmaneuver antimicrobials evasion.

Subject of Research: Genetic determinants of antimicrobial tolerance and resistance in Mycobacterium abscessus.

Article Title: Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.

Article References:
Jovanovic, A., Bright, F.K., Sadeghi, A. et al. Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes. Nat Microbiol (2026). https://doi.org/10.1038/s41564-025-02217-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41564-025-02217-y